Michael Joseph Simon

6932967, Aug 23, 2005

Mar 22, 2001

09/815026

Michael R. Simon - Ann Arbor MI, US

A61K039/00
A61K039/395
C07K016/00
C12P021/08

4241301, 4241781, 530350, 5303891, 5303911

Pooled human plasma is processed by cold ethanol fractionation to produce purified immunoglobulin G antibodies for intravenous administration. Immunoglobulin A is an unwanted by-product since intravenous administration of immunoglobulin A-containing immunoglobulin G can cause life-threatening anaphylaxis in some people. The present invention is the aerosol administration, by metered dose inhaler or nebulizer, of by-product immunoglobulin A for the prevention or treatment of diseases including immunodeficiencies and infections. Antigen-specific monoclonal immunoglobulin A may be used. Immunoglobulin A from any of the aforementioned sources may then be coupled with recombinant J chain, and may then be additionally coupled with recombinant secretory component in order to render the immunoglobulin A more physiologically active. Immunoglobulin A, with or without J chain and secretory component, is then administered by aerosol inhalation.

6967106, Nov 22, 2005

Sep 18, 2002

10/246158

Michael R. Simon - Ann Arbor MI, US

G01N033/563
G01N033/536
A61K039/395
A61K039/00
C12P021/08

436513, 436547, 4241301, 4241781, 435 691

Pooled human plasma is processed by cold ethanol fractionation to produce purified immunoglobulin G antibodies for intravenous administration. Immunoglobulin A is an unwanted by-product since intravenous administration of immunoglobulin A-containing immunoglobulin G can cause life-threatening anaphylaxis in some people. The present invention is the topical application of immunoglobulin A coupled with J chain, and optionally coupled with secretory component in order to render the immunoglobulin A more physiologically active, for the prevention or treatment of ocular diseases including ocular immune deficiency and infections. Antigen-specific monoclonal immunoglobulin A may be used.

7597891, Oct 6, 2009

Aug 16, 2007

11/839781

Michael R. Simon - Ann Arbor MI, US

A61K 39/00
A61K 49/00
A61K 39/02

4241341, 424 91, 424 92, 4241301, 4241391, 4241411, 4241501, 4241781, 4242341, 4242361, 4242391

A composition for treating a subject is provided. The composition includes dimeric or polymeric secretory IgA therapeutic. Formulating agents are mixed with the dimeric or polymeric secretory IgA to yield a dosing form of a capsule, tablet, and a suppository. A process for manufacturing a medicament for the treatment of associated disease in a human is also provided wherein dimeric or polymeric IgA is modified with secretory component to form a dimeric or polymeric secretory IgA therapeutic. The dimeric or polymeric secretory IgA therapeutic is then mixed with formulating agents to create a capsule, tablet, or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.

7794721, Sep 14, 2010

Sep 7, 2007

11/851606

Michael R. Simon - Ann Arbor MI, US

A61K 39/00
A61K 39/395
A61K 39/02

4241781, 424 91, 424 92, 4241301, 4241391, 4241411, 4241501, 4242341, 4242361, 4242391

A composition for treating a subject is provided. The composition includes a pentameric secretory IgM therapeutic. Formulating agents are mixed with the pentameric secretory IgM to yield a dosing form of a capsule, tablet, and a suppository. A process for manufacturing a medicament for the treatment of associated disease in a human is also provided that the modification of pentameric IgM with secretory component to form a pentameric secretory IgM therapeutic. The pentameric secretory IgM therapeutic is then mixed with formulating agents to create a capsule, tablet, or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.

7900601, Mar 8, 2011

May 13, 2009

12/464988

Jesse M. Gwidt - Brighton MI, US
Jonathan T. Shibata - Whitmore Lake MI, US
Michael Simon - Plymouth MI, US
Karen Margaret-Bell Gwidt - Brighton MI, US

F02M 7/28

123435, 123299, 701105

An engine system comprises a temperature determination module, a temperature comparison module, and a fuel injection control module. The temperature determination module determines an engine temperature. The temperature comparison module compares the engine temperature and a temperature threshold. The fuel injection control module adjusts a timing of fuel injection from a first range of an intake stroke to a second range of the intake stroke based on the comparison. The first range and the second range do not overlap.

8021645, Sep 20, 2011

Jun 13, 2008

12/138758

Michael R. Simon - Ann Arbor MI, US
Stephanie M. Chervin - Ann Arbor MI, US
Stephen C. Brown - Ann Arbor MI, US

A61K 49/00
A61K 39/02
A61K 39/08

424 92, 424 91, 4241301, 4241391, 4241401, 4241501, 4241781, 4242341, 4242361, 4242391

A composition for treating a subject is provided. The composition includes antigen specific dimeric secretory IgA and pentameric IgM therapeutic. A process for manufacturing a medicament for the treatment of associated disease in a human is also provided that the modification of antigen specific dimeric secretory IgA and pentameric IgM with secretory component to form a antigen specific dimeric secretory IgA and pentameric secretory IgM therapeutic. The antigen specific dimeric secretory IgA and the pentameric secretory IgM therapeutic is then mixed with formulating agents to create a capsule, tablet, liquid or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.

8119104, Feb 21, 2012

Jan 25, 2011

13/013648

Michael Richard Simon - Ann Arbor MI, US
Mark Andrew Kroenke - Lemon Grove CA, US

A61K 49/00
A61K 39/395
A61K 39/40

424 91, 424 92, 4241301, 4241341, 4241391, 4241411, 4241501

A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating.

8162801, Apr 24, 2012

Feb 22, 2010

12/709807

Sharon Liu - Ann Arbor MI, US
Henry A. Hainer - Ray MI, US
Michael Simon - Plymouth MI, US
Joshua D Cowgill - Hartland MI, US
Douglas R. Verner - Sterling Heights MI, US

B60W 10/06
B60W 10/18

477185, 477203, 1231794, 74 7 A

A control system includes an auto-stop module, an auto-start module, and a starter module. The auto-stop module stops an engine when a brake pedal position is greater than a threshold position and a transmission is in a drive gear. The auto-start module starts the engine when the brake pedal position is less than a minimum position and the engine stop is initiated. When the engine start is initiated and an engine speed is greater than zero, the starter module engages a pinion gear of a starter with a ring gear of an engine by reciprocally actuating the pinion gear N times between a retracted position and an extended position, wherein N is an integer greater than two.